The 18 kDa translocator protein (TSPO) is a target for novel glioblastoma therapies due to its upregulation in this cancer and relatively low levels of expression in the healthy cortex. The pyrazolo[1,5-a]pyrimidine acetamides, exemplified by DPA-713 and DPA-714, are a class of high affinity TSPO ligands with selectivity over the central benzodiazepine receptor. In this study we have explored the potential anti-glioblastoma activity of a library of DPA-713 and DPA-714 analogues, and investigated the effect of amending the alkyl ether chain on TSPO affinity and functional potential. All ligands demonstrated nanomolar affinity for TSPO, but showed diverse functional activity, for example DPA-713 and DPA-714 did not affect the proliferation or viability of human T98G glioblastoma cells, while the hexyl ether and benzyl ether derivatives decreased proliferation of T98G cells without affecting proliferation in human fetal glial SVGp12 cells. These ligands also induced apoptosis and dissipated T98G mitochondrial membrane potential. This suggests that the nature of the alkyl ether chain of pyrazolo[1,5-a]pyrimidine acetamides has little influence on TSPO affinity but is important for functional activity of this class of TSPO ligands.
Introduction
Glioblastoma is the most aggressive type of glioma. The current standard of care for glioblastoma involves a combination of aggressive tumor resectioning, radiotherapy and chemotherapy, and produces a median survival rate of 14.2 months (Johnson and O'Neill, 2012) . Despite the exploration of experimental glioblastoma treatments over the past three decades, the median survival rate has changed only modestly (Omay and Vogelbaum, 2009; Johnson and O'Neill, 2012) , and identification of early diagnostic methods and improved treatments remains a critical unmet clinical need.
The translocator protein (TSPO), previously named the peripheral benzodiazepine receptor, is an 18 kDa outer mitochondrial membrane protein which is involved in the transport of cholesterol into the mitochondria (Papadopoulos et al., 2006) . A range of in vitro and in vivo data implicates TSPO in glioblastoma (Austin et al., 2013; Werry et al., 2015) . TSPO expression is positively correlated with in vivo grade and in vitro tumorigenicity in several glioblastoma cell lines, and negatively correlated with glioblastoma survival rate (Miettinen et al., 1995; Veenman et al., 2004; Vlodavsky and Soustiel, 2007; Su et al., 2013) . Upregulation of TSPO improves the motility and transmigratory capacity of C6 rat glioma cells , and TSPO knockdown decreases the basal proliferative ability of astrocytomas . Furthermore, the selective, high affinity TSPO ligand PK 11195 shows cytostatic effects on a range of glioblastoma cell lines (Ikezaki and Black, 1990; Zisterer et al., 1998; Chelli et al., 2008; Kugler et al., 2008) . The aforementioned studies and the relatively low expression of TSPO in normal cortex (Miyazawa et al., 1998) indicate that TSPO could be a new avenue for molecular imaging and treatment of glioblastoma.
Whilst the isoquinoline carboxamide PK 11195 has been used extensively to study anti-proliferative effects on in vitro glioblastoma, this ligand displays highly variable kinetic behaviour, substantial non-specific binding, and poor bioavailability (Chauveau et al., 2008; Endres et al., 2009) , precluding its use as a TSPO-directed glioblastoma therapy or diagnostic agent. Pyrazolo [1,5-a] pyrimidine acetamides are a newer chemotype, and although they show reduced affinity to the common TSPO polymorphism rs6971 (Owen et al., 2011) , they demonstrate high-affinity for the wild type TSPO and superior selectivity over the central benzodiazepine receptor (Selleri et al., 2001) . Two second generation ligands from this class, DPA-713 and DPA-714 (Table 1) , show good bioavailability, brain penetrability and stability in humans (Endres et al., 2009; Arlicot et al., 2012; Corcia et al., 2012; Endres et al., 2012; Coughlin et al., 2014) .
18
(F)-DPA-714 preferentially accumulates in tumors of glioma-bearing rats, and levels correlate with ex vivo assays of TSPO levels in these gliomas, suggesting DPA-714 could be a promising glioblastoma imaging agent (Tang et al., 2012; Winkeler et al., 2012; Awde et al., 2013) . DPA-714, but not DPA-713, stimulated pregnenolone release from rat C6 glioma cells (James et al., 2008; Reynolds et al., 2010) . Although the role of TSPO in pregnenolone stimulation in vivo has recently been questioned (Banati et al., 2014) , these in vitro results suggest the nature of the alkyl ether group may be key to producing TSPO ligands within this class which are functionally active at glioblastomas. The aim of the current work was to examine the cytostatic and cytotoxic properties of DPA-713 and DPA-714 on a human glioblastoma cell line that endogenously expresses the wild type TSPO (Narlawar et al., 2015) , and to use a recently described library of alkyl ether analogues of DPA-713 (Reynolds et al., 2010; Banister et al., 2015) to characterize the effect of the alkyl ether chain of DPA-713 on the anti-glioblastoma properties of this chemotype.
Method

Cell culture
The human glioblastoma cell line, T98G, and the human fetal glial cell line, SVG p12, were kindly donated by A/Prof. Lou Rendina (School of Chemistry, University of Sydney). T98G cells were maintained in Dulbecco's modified Eagle's medium: Ham's Nutrient Mixture F-12 (Invitrogen, Carlsbad, CA) and supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen; 10% DMEM/F12). SVGp12 cells were maintained in Minimum Essential Medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (10% MEM). Once cells reached the exponential phase of growth they were washed with phosphate-buffered saline (PBS, Sigma-Aldrich, St. Louis, MO) and were detached with 0.25% trypsin (w/v)/0.02% ethylenediaminetetraacetic acid (EDTA) (w/v). Cells were plated at a density of 1 × 10 4 cells/well in 96-well plates (Falcon Bioquest, Cockeysville, MD) and allowed to attach for 24 h before assaying.
Compounds
PK 11195 was purchased from Sigma-Aldrich. DPA-713, DPA-714 and compounds 1-7 (Table 1) were synthesised using described methodology (Reynolds et al., 2010; Banister et al., 2012; Banister et al., 2015) . All compounds were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) and for viability, proliferation, apoptosis and mitochondrial membrane potential assays, compounds were further diluted in 10% DMEM/F12 or 10% MEM. The final DMSO concentration was either 0.1% (PK 11195, DPA-713, compounds 1, 3 and 4) or 0.2% (DPA-714, 2, 5, 6 and 7), depending on solubility. DMSO at 0.1% and 0.2% did not significantly affect results in any of the functional assays. Cells were treated with at a range of concentrations (1 μM, 10 μM, 25 μM, 50 μM, 75 μM and 100 μM), or treated with vehicle control (0.1% or 0.2% DMSO) (v/ v). Treated cells were incubated for 48 h in 5% CO 2 at 37°C for proliferation, viability and apoptosis assays, and were incubated for 6 h and 24 h in the mitochondrial membrane potential assay.
Radioligand binding
Membrane preparation
For crude membrane preparation, T98G cells were grown to confluence and harvested using phosphate-buffered saline, supplemented with 0.04% EDTA (w/v), pH 7.4. Cells were spun at 1000 g for 10 min and the pellet was suspended in 3 ml of ice-cold 5 mM Tris-HCl (pH 7.4) containing a protease inhibitor cocktail (1:100; Sigma-Aldrich). Cells were homogenised with a hand-held Ultra-Turrax homogeniser (IKA Werke, Staufen, Germany). The homogenate was centrifuged at 48,000 g for 15 min at 4°C and the supernatant was discarded. The obtained pellet was resuspended in 10 ml of 50 mM Tris-HCl (pH 7.4; binding assay buffer), containing the protease inhibitor cocktail. The homogenate was re-pelleted by centrifugation at 48,000 g for 15 min at 4°C. The pellet was washed once with binding assay buffer and an additional centrifugation step followed where the homogenate was spun at 48,000 g for 15 min at 4°C. Total protein in the resulting cell membrane pellet was determined using the bicinchoninic acid protein assay (Pierce Biotechnology Inc., Rockford, IL) according to the manufacturer's protocol. ] PK 11195 (Perkin-Elmer, Beaconsfield, UK) at seven concentrations between 0.1 and 24 nM, in the presence of 3 μM unlabelled PK 11195 (Sigma-Aldrich) to establish non-specific binding, or a vehicle control (1.4% DMSO) (v/v) to establish total binding. The reaction was incubated for 90 min at 4°C to achieve equilibrium, terminated by rapid filtration through a glass-fibre filter (GF/C; Millipore, Carrigtwonhill, Ireland) and washed with 50 mM Tris-HCl (pH 7.4), at 4°C. The filters were then allowed to dry overnight, and covered with Microscint-0 scintillation cocktail (Perkin-Elmer). The amount of radioactivity retained on the filters was determined using a Microbeta 2 2450
Microplate Counter (Perkin-Elmer).
Competition binding
T98G cell membranes (20 μg/well) and [ 3 H] PK 11195 (PerkinElmer) at 12 nM (K d determined in Section 2.3.1) were incubated with 3 μM of PK 11195 (Sigma-Aldrich) to assess non-specific binding, a vehicle control (DMSO 1.4% (v/v)) to establish total binding, and test compounds at ten concentrations between 0.1 and 3162 nM. The reaction was incubated for 90 min at 4°C. The incubation was terminated by rapid filtration through a glass-fibre filter (Millipore) and washed with 50 mM Tris-HCl (pH 7.4) at 4°C. The filter was then covered with scintillation cocktail (Perkin-Elmer). The amount of radioactivity retained on the filters was determined using a Microbeta 2 2450 Microplate Counter (Perkin-Elmer).
Cell proliferation assay
5-bromo-2′-deoxyuridine (BrdU) is incorporated into DNA as a substitute for thymidine during cell proliferation. After cells proliferate in the presence of BrdU, detection of BrdU in DNA using an ELISA (Roche Molecular Diagnostics, Indianapolis, IN) can be used as an index of proliferation. After 48 h of exposure to compounds, cells were incubated with 10 μl of BrdU (1:100) at 37°C for 4 h. Cells were then fixed and DNA was denatured for 30 min. A peroxidase-conjugated anti-BrdU antibody (1:100) was subsequently added to the cells for 90 min. The cells were then washed three times with PBS and the substrate solution, 3,3′,5,5′-tetramethylbenzidine, was added for 20 min. The reaction was stopped with 1 M sulfuric acid and the absorbance was measured on a POLARstar Omega plate reader (BMG Labtech) at 450 nm.
Cell viability assay
Viable cells will metabolise the dye resazurin to the fluorescent molecule resorufin. Measuring the fluorescence from resorufin can be used to compare the number of viable cells across different conditions. Following 48 h of drug treatment, 20 μl of resazurin-containing CellTiter Blue (Promega, Madison, WI) was added to cells and incubated for 4 h in 5% CO 2 , at 37°C. The supernatant (100 μl) was then transferred to a black-well plate and fluorescence was measured on a POLARstar Omega plate reader (BMG Labtech, Durham, NC) at Ex560/Em590 nm.
Apoptosis assay
During apoptosis, DNA is cleaved generating mono-and oligo-nucleosomes. The Cell Death ELISA (Roche Molecular Diagnostics) uses antibodies to detect the presence of these nucleosomes. This assay was conducted following 48 h cell treatment. A streptavidin-coated 96-well plate was coated with a biotinylated anti-histone antibody (1:100) and incubated for 1 h. Cells were lysed, incubation media collected, spun at 200 g for 10 min and the supernatant collected. The coated 96-well plate was washed three times with PBS and supernatants were added for 90 min. The plate was washed again and a peroxidaseconjugated anti-DNA antibody (1:100) was added for 90 min. After a subsequent wash the substrate solution, 3-ethylbenzothiazoline-6-sulphonic acid, was added for 20 min. The absorbance was read on a POLARstar Omega plate reader (BMG Labtech) at 405 nm and values expressed as apoptotic index, a measure of fold change relative to vehicle-treated cells.
Dissipation of mitochondrial membrane potential
Healthy mitochondria maintain a mitochondrial transmembrane potential (ΔΨ m ), allowing the synthesis of ATP. Cells in the early stage of the intrinsic pathway of apoptosis show a dissipation of ΔΨ m and will not accumulate a fluorescent MitoPotential Dye that otherwise shows high fluorescence in healthy cells. Furthermore, dead cells which have lost membrane structural integrity will uptake the fluorescent dead cell marker 7-AAD. The Muse MitoPotential assay uses flow cytometry to assess the portion of cells that have accumulated MitoPotential Dye and/or 7-AAD, to classify cells as live, live but with dissipated ΔΨ m , dead with dissipated ΔΨ m and dead.
T98G cells were plated at 5 × 10 4 cells per well of a 48-well plate in 250 μl per well of 10% DMEM/F12. Twenty-four hours after plating, 100 μM compounds or vehicle were added to cells and left for 6 or 24 h. After incubation, the supernatant was collected and cells were washed in 200 μl PBS which was collected. Cells were exposed to 200 μl of 0.25% trypsin (w/v)/0.02% ethylenediaminetetraacetic acid (EDTA) (w/v) for 10 min at 37°C, then washed with 350 μl 10% DMEM/F12. The trypsin and media were pooled with the solutions already collected and were spun at 1200 rpm for 5 min. The supernatant was discarded and cells were resuspended in 10% DMEM/F12 at 5 × 10 5 cells/ml. One hundred microliters of cell suspension were added to 95 μl of a 1:1000 dilution of Muse MitoPotential Dye diluted in assay buffer. This was incubated for 20 min at 37°C, then 5 μl of 7-AAD was added. After a 10 min incubation, cells were acquired by the Muse cell analyzer and the percentage of each cell state was analyzed according to the manufacturer's protocol.
Microscopy
After 48 h drug treatment (100 μM), morphological changes were documented using differential interference contrast (DIC) microscopy. A Zeiss Axio Observer Live Cell Imaging System (Zeiss, Göttingen, Germany) was used, with the objective lens A-Plan 10 ×/0.25 Ph1. Cells were imaged in optimal conditions, at 37°C and 5% CO 2 .
Statistical analysis
All assay conditions were tested in triplicates and means were calculated. Each condition was tested on at least three independent occasions and final mean and standard deviation (SD) values were determined. GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, U.S.A.) was used for statistical analysis. Saturation binding was analyzed using a non-linear regression curve fit to determine the K d and B max . Competition binding was analyzed with a four-parameter non-linear regression curve fit to identify the K i for each compound. The sum of squares F-test was used to assess whether a one or two-site model best fit the competition data. For the viability, proliferation, and apoptosis assays, average basal absorbance for each condition was subtracted to remove background readings. To compare group means in these assays, as well as in the mitochondrial membrane potential assay, a one-way analysis of variance (ANOVA) with a post-hoc Dunnett's test was used. In addition, a Sidak's multiple comparisons test was used to compare proliferation levels in T98G and SVG p12 cells. Statistically significant differences were considered as p b 0.05. Data is expressed as mean ± standard deviation (SD).
Results
Radioligand binding
The binding of the ligand [ 3 H]-PK 11195 to T98G membranes yielded an equilibrium dissociation constant (K d ) of 11.5 ± 1.2 nM and maximum number of binding sites (B max ) of 1132.3 ± 187.7 fmol/mg protein. All compounds bound to TSPO with low nanomolar affinity with the rank order of affinity appearing independent of the nature and length of the R-substituent (Table 1 ). The sums of squares F-test rejected a two-site model for each of the compounds in favour of a one-site fit.
Cell proliferation
Measurement of BrdU incorporation using an ELISA was used to assess the anti-proliferative effects of these high affinity TSPO ligands in the human glioblastoma cell line T98G. Furthermore, we assessed the anti-proliferative effects of these ligands on the human fetal astroglial cell line SVG p12 which can be used to investigate the undesirable effects of potential anti-glioblastoma agents on non-cancerous glial cell lines (Mehta et al., 2011; Borawska et al., 2014) . DPA-713, DPA-714, 1 and 2 did not induce a change in proliferation in either SVG p12 or T98G cells, although 2 could only be assayed at 75 μM due to solubility limitations. 3 and 6 significantly decreased proliferation in both SVG p12 and T98G cells, with proliferation decreased to a similar extent in both cell lines. 4 significantly decreased proliferation in SVG p12 cells, but produced a significantly greater decrease in proliferation in T98G cells. PK 11195, 5 and 7 did not significantly change proliferation in SVG p12 cells, while significantly decreasing proliferation in T98G cells (Fig. 1A) . These 3 compounds were also the only compounds to dosedependently decrease proliferation in T98G cells in a manner potent enough for IC 50 's to be calculated (Fig. 1B) . 5 decreased proliferation with an IC 50 of 64.6 ± 1.6 μM, 7 decreased proliferation with an IC 50 of 71.5 ± 0.5 μM and PK 11195 decreased proliferation with an IC 50 of 87.3 ± 4.5 μM.
Cell viability
To gain insight into whether these compounds only produced cytostatic effects, we investigated the effect of these compounds on cell viability and measures of apoptosis. Surprisingly, PK 11195 did not produce any significant decrease in the number of viable T98G cells, Fig. 1 . The effect of pyrazolopyrimidine derivatives on SVG p12 and T98G proliferation. Both cell lines were treated for 48 h with 100 μM. ***p b 0.001 when percentage of proliferation in T98G cells was compared to that in SVG p12 cells using a one-way ANOVA with Sidak's multiple comparisons test (A). Compounds producing significant decreases in proliferation were further assessed across a range of concentrations (50-100 μM), and those potent enough to produce IC 50 's are displayed in (B). Values represent the mean ± SD, from three independent experiments. despite its ability to decrease proliferation. The pyrazolopyrimidine-derivatives that showed reduced BrdU incorporation also showed reductions in the number of viable cells present after 48 h treatment, albeit their effect was less potent than on BrdU incorporation (Fig. 2) . 5 and 7 reduced the number of viable cells with IC 50 's of 75.9 ± 1.5 and 93.7 ± 5.9 μM respectively.
Apoptosis
We next examined whether decreases in BrdU incorporation and the number of viable cells was due to apoptosis using a Cell Death ELISA which detects mono-and oligo-nucleosomes, representative of DNA fragmentation created during apoptosis. Compounds 3-7 caused a 3 to 4-fold increase in DNA fragmentation at 100 μM compared to vehicle (Fig. 3) , while PK 11195 had no effect.
Dissipation of mitochondrial membrane potential
Apoptosis can occur through an intrinsic and extrinsic pathway. One key point of difference between these two pathways is the role of mitochondria, with the intrinsic pathway featuring opening of the mitochondrial permeability transition pore and dissipation of the mitochondrial membrane potential in the early stages of apoptosis (Elmore, 2007) . We used flow cytometry to investigate whether any of the pro-apoptotic compounds, as well as PK 11195, dissipated the mitochondrial membrane potential. After 6 h of treatment at 100 μM, the two most potent compounds (5 and 7) were the only two compounds to induce lowered levels of healthy live cells and more live cells with depolarized mitochondria (Fig. 4A) . Compounds 3, 4 and 6 showed a delayed induction of mitochondrial depolarization, inducing significant decreases in the number of healthy live cells and more live cells with depolarized mitochondria after 24 h of treatment (Fig. 4B ). In congruence with its lack of induction of apoptosis, PK 11195 did not show any effect on mitochondrial membrane potential (Fig. 4) .
Morphology
Different morphological changes were observed in T98G cells treated with 100 μM PK 11195 and compounds 3-7. PK 11195 caused cells to become elongated, spindle-like and extended processes were evident, while cells treated with compounds 3-7 showed morphological changes such as rounding and blebbing (Fig. 5) .
Discussion
Extending the length and nature of the alkyl ether substituent of DPA-713 has minimal influence on affinity for human TSPO, with all derivatives binding with low nanomolar affinity, suggesting a steric tolerance of the alkyl ether substituent during binding. Increasing the number of carbons in the alkyl ether substituent, however, creates a functionally diverse group of ligands. Having up to 3 carbons in the alkyl ether substituent leads to a subgroup of ligands that do not have pro-apoptotic and anti-proliferative effects in the human glioblastoma cell line T98G. Increasing the number of carbons to 4 or 5 produces compounds that induce apoptosis after a delayed dissipation of mitochondrial membrane potential, and show anti-proliferative effects in both T98G cells and a human fetal astroglial cell line, SVG p12. The effect on SVG p12 cells indicate 4 or 5 carbon substituents may produce unwanted effects on non-cancer cells, although the extent to which these are TSPO-mediated is not clear as the level of TSPO expression in these cells is currently unknown. Finally, increasing the number of carbons to 6 or 7 produces a subgroup of compounds that show early induction of glioblastoma membrane potential dissipation and apoptosis. These compounds also cause greatly reduced BrdU incorporation in T98G cells in a manner more potent than PK 11195. While it is not clear the extent to which the reduction in BrdU incorporation is due to cytostatic effects given their pronounced cytotoxic effects, these compounds do not affect BrdU incorporation in SVG p12 cells.
The mechanisms behind the diverse functional outcomes of alkyl ether carbon number variation are not clear. Recently, evidence has accumulated suggesting functional activity of TSPO ligands can be predicted by residence time -the amount of time the ligand interacts with TSPO Costa et al., 2016) . Costa et al. (2014) demonstrated that increasing the residence time of a TSPO ligand, PIGA, facilitated the impairment of glioblastoma viability at lower doses and allowed it to dissipate mitochondrial membrane potential at earlier time points (3-6 h vs 12-24 h). The residence time of the pyrazolopyrimidine derivatives in this present study are unknown, however the induction of mitochondrial membrane potential dissipation by the higher potency compounds at 6 h compared to induction at 24 h by the lower potency compounds mirrors the change in dissipation time seen by lowering PIGA residence time, suggesting that residence time may be a factor that contributes to functional differences in these compounds. Further, residence time has been shown to predict pregnenolone synthesis efficacy in a class of TSPO ligands (Costa et al., 2016) . All compounds showing anti-glioblastoma effects in this present study induce pregnenolone release N200% over basal levels, apart from 5 whose effect on pregnenolone release has not been examined (Reynolds et al., 2010; Banister et al., 2015) , while all compounds that do not induce anti-glioblastoma effects in this present study stimulated lower pregnenolone levels, apart from 1 (Reynolds et al., 2010; Banister et al., 2015) . Hence this may be further evidence that residence time may contribute to the functional diversity of these compounds. Surprisingly, the high affinity TSPO ligand PK 11195 demonstrated distinctly different anti-glioblastoma properties to the pyrazolopyrimidine acetamide derivatives. PK 11195 did not display cytotoxic properties, with its outcomes restricted to cytostatic effects. Up regulation of TSPO levels increases glioblastoma proliferation, while downregulation has the opposite effect , with neither of these interventions affecting viability. Prolonged exposure to PK 11195 can decrease TSPO levels in breast cancer cell lines (Xu et al., 2016) , so if PK 11195 has a similar effect on TSPO levels in glioblastoma cells, then it is possible that its distinct effects may be related to its effect on TSPO levels.
The most potent of the pyrazolopyrimidine analogues had micromolar potency, despite their low nanomolar affinity for TSPO. While this may suggest these anti-glioblastoma effects are not through TSPO specific pathways, there is precedent for discrepancies between affinity and potency when examining the anti-cancer effects of TSPO ligands. PK 11195 has a low nanomolar affinity for TSPO, but an EC 50 of 50-100 μM for anti-proliferative and pro-apoptotic effects on many different glioma cell lines (Zisterer et al., 1998; Chelli et al., 2008; Kugler et al., 2008) . The anti-proliferative and mitochondrial stressor effect of high micromolar concentrations of PK 11195 was prevented by TSPO silencing , suggesting these effects were mediated through TSPO. Also, a recently described 4-phenyl quinazoline-2-carboxamide with high affinity for the TSPO decreased U343 glioblastoma viability at micromolar concentrations without off-target activation of G-proteins or a panel of thirteen human kinases linked to glioblastoma (Castellano et al., 2014) . Interestingly, even though many TSPO ligands have micromolar potencies in anti-cancer assays in vitro, they are still effective at restricting tumor progression in vivo (Xia et al., 2000; Decaudin et al., 2002; Shoukrun et al., 2008) .
The affinity of compound 1 for human TSPO was comparable to TSPO extracted from rat kidney mitochondria (Reynolds et al., 2010; Banister et al., 2015) , however affinities for DPA-713, DPA-714 and the other pyrazolopyrimidine acetamide derivatives differed by two-to elevenfold from this study. The K i of DPA-713 in our study more closely resembled the affinity found on binding of [ 3 H]-DPA-713 to human TSPO from monocytic THP-1 cells (Gent et al., 2014) . Although the amino acid sequence of TSPO is highly conserved between species (Farges et al., 1994) , differences in affinity for rat and human TSPO have been reported for other classes of heteroaromatic TSPO ligands, such as pyrrolobenzoxazepines (Scarf et al., 2012) . Given the structural similarity between the pyrrolobenzoxazepines and the pyrazolopyrimidines evaluated in the present study, species differences in TSPO affinity might be expected. This also suggests that small differences in amino acid sequence between rat and human TSPO may profoundly modulate ligand binding.
[
I]-DPA-713 and [
18 F]-DPA-714 were recently used in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) respectively, to image glioma in pre-clinical murine models (Tang et al., 2012; Winkeler et al., 2012; Awde et al., 2013; O'Brien et al., 2014) . These compounds did not affect glioblastoma and astroglial cell proliferation or survival in our assays, highlighting their potential utility as clinical glioblastoma imaging candidates. Results from the current study also suggest that 1 may be a more suitable glioblastoma imaging candidate given its lack of functional activity and relatively higher TSPO affinity compared to DPA-713 and DPA-714.
Conclusions
In summary, we have shown that nine pyrazolo[1,5-a]pyridine acetamides substituted with variously alkyl ethers demonstrate nanomolar affinity to human TSPO, indicating that further exploration of the ether group of this chemotype is warranted and likely to be tolerated. By extending the alkyl ether chain we have produced a functionally diverse class of derivatives, some of which induce pro-apoptotic and potentially cytostatic effects on human glioblastoma cells without affecting human astroglial cells. While these ligands may not be candidate therapeutics, future development of this class as potential therapeutic agents for the treatment of glioblastoma could focus on further exploration and structural diversification of the alkyl ether substituent. 
